Select Page

South Delhi Pharma, New Delhi, India

Dupixent (dupilumab)

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

Facts of Dupixent (dupilumab)

DUPIXENT® (dupilumab) injection, for subcutaneous use
Initial U.S. Approval: 2017
• Injection: 300 mg/2 mL solution in a single-dose pre-filled syringe with needle shield
• Injection: 300 mg/2 mL solution in a single-dose pre-filled syringe
Company Regeneron

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Dupixent (dupilumab)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Dupixent (dupilumab) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

What DUPIXENT is?

DUPIXENT is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose
disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or
without topical corticosteroids.

What dupilumab is?

Dupilumab, sold under the trade name Dupixent, is a monoclonal antibody used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis.
Dupilumab appears to be useful for moderate-to-severe atopic dermatitis for which it is approved in the United States.] It is also being evaluated for treatment of persistent asthma in adults and adolescents. In October 2019, the European Commission (EC) approved Dupixent in chronic rhinosinusitis with nasal polyposis (CRSwNP).

Reviews

There are no reviews yet.

Be the first to review “Dupixent (dupilumab)”

Your email address will not be published.